Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
-
ABL1 MUTATION
ABL1 MUTATION - Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Among 39 patients with mutational analysis at baseline, subsets were evaluated for complete hematologic response (CHR) and major cytogenetic response (MCyR). Both were comparable for patients with Abl1 mutation versus without [CHR = 26/39 (67%) vs. 34/44 (77%); MCyR = 11/35 (31%) vs. 15/43 (35%)]. The authors observe responses with bosutanib monotherapy across many BCR-ABL mutations with the notable exception of T315I.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6996
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2371
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Does Not Support
- Drug
- Bosutinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 22371878
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bosutinib | Resitance or Non-Reponse | false |